This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2009 Jun;36(6):1107-8.

doi: 10.3899/jrheum.090119.

Biologic agents in the treatment of rheumatic diseases with chronic viral infection. Where are we?

Daniel Wendling, Vincent Di Martino, Georges Herbein

PMID: 19509089
DOI: 10.3899/jrheum.090119

Editorial

Biologic agents in the treatment of rheumatic diseases with chronic viral infection. Where are we?

Daniel Wendling et al. J Rheumatol. 2009 Jun.

. 2009 Jun;36(6):1107-8.

doi: 10.3899/jrheum.090119.

Authors

Daniel Wendling, Vincent Di Martino, Georges Herbein

PMID: 19509089
DOI: 10.3899/jrheum.090119

No abstract available

PubMed Disclaimer

Comment in

Tocilizumab for rheumatoid arthritis with chronic hepatitis B virus infection without antiviral therapy.
Nagashima T, Minota S. Nagashima T, et al. J Rheumatol. 2010 May;37(5):1066; author reply 1067. doi: 10.3899/jrheum.091220. J Rheumatol. 2010. PMID: 20439526 No abstract available.

Comment on

Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airò P. Zingarelli S, et al. J Rheumatol. 2009 Jun;36(6):1188-94. doi: 10.3899/jrheum.081246. Epub 2009 May 15. J Rheumatol. 2009. PMID: 19447932 Review.

Similar articles

Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections.
Vassilopoulos D, Calabrese LH. Vassilopoulos D, et al. Curr Opin Rheumatol. 2007 Nov;19(6):619-25. doi: 10.1097/BOR.0b013e3282f05b63. Curr Opin Rheumatol. 2007. PMID: 17917544 Review.
Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airò P. Zingarelli S, et al. J Rheumatol. 2009 Jun;36(6):1188-94. doi: 10.3899/jrheum.081246. Epub 2009 May 15. J Rheumatol. 2009. PMID: 19447932 Review.
[Immunosupression and viral infections in rheumatic diseases].
Vince A, Dusek D. Vince A, et al. Reumatizam. 2007;54(2):58-62. Reumatizam. 2007. PMID: 18351141 Review. Croatian.
[Do DMARDs contibute to impaired healing after surgery? Should they be discontinued before surgery?].
Glück T, Müller-Ladner U. Glück T, et al. Dtsch Med Wochenschr. 2007 Sep;132(37):1901-4. doi: 10.1055/s-2007-985615. Dtsch Med Wochenschr. 2007. PMID: 17823884 Review. German. No abstract available.
MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
Sfriso P, Salaffi F, Montecucco CM, Bombardieri S, Todesco S. Sfriso P, et al. Reumatismo. 2009 Apr-Jun;61(2):132-9. Reumatismo. 2009. PMID: 19633800

See all similar articles

Cited by

Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy.
Manzano-Alonso ML, Castellano-Tortajada G. Manzano-Alonso ML, et al. World J Gastroenterol. 2011 Mar 28;17(12):1531-7. doi: 10.3748/wjg.v17.i12.1531. World J Gastroenterol. 2011. PMID: 21472116 Free PMC article. Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire
Medical
- MedlinePlus Health Information